Aude Fléchon

25.1k total citations · 3 hit papers
273 papers, 7.7k citations indexed

About

Aude Fléchon is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Aude Fléchon has authored 273 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 167 papers in Surgery, 139 papers in Pulmonary and Respiratory Medicine and 113 papers in Oncology. Recurrent topics in Aude Fléchon's work include Testicular diseases and treatments (75 papers), Bladder and Urothelial Cancer Treatments (75 papers) and Prostate Cancer Treatment and Research (65 papers). Aude Fléchon is often cited by papers focused on Testicular diseases and treatments (75 papers), Bladder and Urothelial Cancer Treatments (75 papers) and Prostate Cancer Treatment and Research (65 papers). Aude Fléchon collaborates with scholars based in France, United States and United Kingdom. Aude Fléchon's co-authors include Karim Fizazi, Cora N. Sternberg, Johann S. de Bono, Fred Saad, Kurt Miller, Kim N., Neal D. Shore, Ronald de Wit, John D. Hainsworth and Andrew J. Armstrong and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Aude Fléchon

257 papers receiving 7.6k citations

Hit Papers

Increased Survival with E... 2012 2026 2016 2021 2012 2021 2018 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
    2012 3.3k citations Karim Fizazi, Cora N. Sternberg et al. profile →
  2. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
    2021 351 citations Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology profile →
  3. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
    2018 281 citations Robert H. Jones, Aude Fléchon et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Aude Fléchon 4.9k 2.6k 2.0k 1.8k 1.6k 273 7.7k
Scott North 5.5k 1.1× 2.8k 1.1× 1.2k 0.6× 2.6k 1.4× 1.2k 0.8× 193 7.6k
Christine Théodore 6.0k 1.2× 3.5k 1.3× 3.9k 2.0× 2.1k 1.2× 1.6k 1.0× 164 10.5k
Jorge A. García 6.2k 1.3× 2.1k 0.8× 1.1k 0.5× 2.6k 1.4× 1.4k 0.9× 213 8.1k
Gwénaëlle Gravis 6.3k 1.3× 3.4k 1.3× 1.4k 0.7× 2.2k 1.2× 1.8k 1.1× 368 9.2k
Mustafa Özgüroğlu 7.8k 1.6× 4.5k 1.7× 906 0.5× 1.4k 0.8× 2.4k 1.6× 258 10.2k
Eleni Efstathiou 4.7k 0.9× 2.4k 0.9× 615 0.3× 2.0k 1.1× 1.3k 0.8× 203 7.4k
Philippe Beuzeboc 3.2k 0.7× 3.9k 1.5× 1.6k 0.8× 1.2k 0.7× 1.4k 0.9× 243 7.6k
Joan Carles 3.1k 0.6× 2.4k 0.9× 2.5k 1.3× 1.2k 0.7× 902 0.6× 327 6.2k
I. Bodrogi 6.4k 1.3× 3.6k 1.4× 2.4k 1.2× 4.3k 2.4× 1.1k 0.7× 78 10.3k
Simon Chowdhury 4.0k 0.8× 1.4k 0.5× 763 0.4× 1.0k 0.6× 1.3k 0.8× 199 5.1k

Countries citing papers authored by Aude Fléchon

Since Specialization
Citations

This map shows the geographic impact of Aude Fléchon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aude Fléchon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aude Fléchon more than expected).

Fields of papers citing papers by Aude Fléchon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aude Fléchon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aude Fléchon. The network helps show where Aude Fléchon may publish in the future.

Co-authorship network of co-authors of Aude Fléchon

This figure shows the co-authorship network connecting the top 25 collaborators of Aude Fléchon. A scholar is included among the top collaborators of Aude Fléchon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aude Fléchon. Aude Fléchon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fléchon, Aude, G. Pignot, J. Rigaud, et al.. (2025). Primary urethral cancer: Treatment patterns, responses and survival in localized, advanced and metastatic patients. BJUI Compass. 6(7). e70056–e70056.
2.
Chabaud, Sylvie, Aude Fléchon, Helen Boyle, et al.. (2025). Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin. European Journal of Cancer. 222. 115427–115427. 1 indexed citations
3.
4.
Loriot, Yohann, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.. (2024). A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer. Future Oncology. 20(23). 1621–1631. 1 indexed citations
5.
Savoie, P.-H., T. Murez, L. Rocher, et al.. (2024). French AFU Cancer Committee Guidelines – Update 2024–2026 : Assessment of an adrenal incidentaloma and oncological management. PubMed. 34(12). 102748–102748. 2 indexed citations
6.
Neuville, P., T. Murez, L. Rocher, et al.. (2024). Primary urethral carcinoma: Recommendations of the oncology committee of the French Urology Association. PubMed. 34(5). 102606–102606. 2 indexed citations
7.
Agarwal, Neeraj, Daniel Castellano, Teresa Alonso‐Gordoa, et al.. (2024). A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1. Clinical Cancer Research. 30(11). 2377–2383. 6 indexed citations
8.
Fizazi, Karim, Gwénaël Le Teuff, Aude Fléchon, et al.. (2024). Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 42(28). 3270–3276. 4 indexed citations
9.
10.
11.
12.
Giraudet, Anne‐Laure, Armelle Vinceneux, Jean‐Noël Badel, et al.. (2023). Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma. Pharmaceuticals. 16(7). 995–995. 6 indexed citations
13.
Fizazi, Karim, Alice Bernard‐Tessier, Guilhem Roubaud, et al.. (2023). Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. NEJM Evidence. 3(1). EVIDoa2300171–EVIDoa2300171. 13 indexed citations
14.
Faure‐Conter, Cécile, Daniel Orbach, Hélène Sudour‐Bonnange, et al.. (2022). Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocol. Pediatric Blood & Cancer. 70(3). e30117–e30117. 3 indexed citations
15.
Savoie, P.-H., T. Murez, P. Neuville, et al.. (2022). French AFU Cancer Committee Guidelines - Update 2022-2024: penile cancer. Progrès en Urologie. 32(15). 1010–1039. 4 indexed citations
16.
Savoie, P.-H., T. Murez, P. Neuville, et al.. (2022). French AFU Cancer Committee Guidelines Update 2022–2024: Adrenal tumor –  Assessment of an adrenal incidetaloma and oncological management. Progrès en Urologie. 32(15). 1040–1065. 3 indexed citations
17.
Carril-Ajuria, Lucía, Émeline Colomba, Luigi Cerbone, et al.. (2021). Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma. European Journal of Cancer. 151. 106–114. 24 indexed citations
18.
Khalifa, Jonathan, Aude Fléchon, & Christine Chevreau. (2020). Brain metastases from germ cell tumor: time to reconsider radiotherapy?. Critical Reviews in Oncology/Hematology. 150. 102946–102946. 5 indexed citations
19.
Chevreau, Christine, Sophie Broutin, Jérôme Guitton, et al.. (2017). Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. Clinical Cancer Research. 23(23). 7171–7179. 14 indexed citations
20.
Fléchon, Aude, et al.. (2010). Uncommon bladder tumours. Bulletin du Cancer. 51–57. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott North Breakdown of academic impact, for papers by Christine Théodore Breakdown of academic impact, for papers by Jorge A. García Breakdown of academic impact, for papers by Gwénaëlle Gravis Breakdown of academic impact, for papers by Mustafa Özgüroğlu Breakdown of academic impact, for papers by Eleni Efstathiou Breakdown of academic impact, for papers by Philippe Beuzeboc Breakdown of academic impact, for papers by Joan Carles Breakdown of academic impact, for papers by I. Bodrogi Breakdown of academic impact, for papers by Simon Chowdhury
Rankless by CCL
2026